Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | President and COO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,802 |
Ending reported balance
After 2026-10-13 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 2 · 2026-10-09 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-10-12 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 4 · 2026-10-12 · Sale · Disposed 9,181 · Balance 380,502 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-12 · Sale · Disposed 2,700 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-10-13 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 7 · 2026-10-13 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 296,610 |
Reported balance
After 2026-10-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-09 · Exercise / conversion · Disposed 11,881 · Balance 296,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 284,729 |
Reported balance
After 2026-10-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-12 · Exercise / conversion · Disposed 11,881 · Balance 284,729 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 272,848 |
Reported balance
After 2026-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-13 · Exercise / conversion · Disposed 11,881 · Balance 272,848 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,885 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $12.63 | $240,727.80 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,216 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,607 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 16,322 | $13.48 | $220,020.56 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,554 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,738 | $12.49 | $34,197.62 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,876 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 22:56 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 483,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,329 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.12 | $269,127.20 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,892 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.82 to $14.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 26, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 487,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,051 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.27 | $271,986.20 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,230 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,773 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.70 | $261,122.00 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,568 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 23:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,495 Underlying: Common Stock · 14,722 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.83 | $263,599.80 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 481,906 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $7.27 | $107,028.94 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 10,783 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,217 Underlying: Common Stock · 10,783 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 3,939 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,939 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.37 | $254,832.20 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 486,244 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,783 | $7.27 | $78,392.41 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 505,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,939 | $6.55 | $25,800.45 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,939 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.18 | $251,210.80 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 490,582 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 509,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 18, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,661 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 18, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.18 | $251,210.80 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,920 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 18, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 513,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,383 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.40 | $255,404.00 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,258 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 518,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,105 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.41 | $255,594.60 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 503,596 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 13, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,827 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 13, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $12.96 | $247,017.60 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 507,934 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 13, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 526,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,549 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,400 | $13.43 | $72,522.00 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 512,272 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.76, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 13,660 | $12.63 | $172,525.80 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 517,672 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.11 to $13.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 531,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,271 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.08 | $268,364.80 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 516,610 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.83 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 01:36 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 122,523 | $13.17 | $1,613,627.91 |
DisclosureSEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 520,948 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 15 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,539 Underlying: Common Stock · 400 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 14 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,993 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,460 | $14.68 | $285,672.80 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 643,471 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.22 to $15.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.